US23954D1090 - Common Stock
DAY ONE BIOPHARMACEUTICALS I
NASDAQ:DAWN (10/29/2024, 7:09:57 PM)
After market: 14.5799 +0.23 (+1.6%)14.35
-0.12 (-0.83%)
Day One Biopharmaceuticals, Inc. operates as a holding company. The company is headquartered in Brisbane California, California and currently employs 174 full-time employees. The company went IPO on 2021-05-27. The firm partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its product candidates include tovorafenib, pimasertib and the VRK1 program. The Company’s lead product candidate, tovorafenib, is an investigational, oral, brain-penetrant, highly selective type II RAF kinase inhibitor. The Company’s pipeline also includes pimasertib, an investigational, oral, highly selective small molecule inhibitor of mitogen-activated protein kinases 1 and 2 (MEK-1/-2). The company has initiated an open-label, multicenter, phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib as a monotherapy or in combination, which consists of two substudies. Substudy 1 is a phase IIa trial of tovorafenib as a monotherapy in patients 12 years and older.
DAY ONE BIOPHARMACEUTICALS I
2000 Sierra Point Parkway, Suite 501
Brisbane California CALIFORNIA
P: 16504840899
CEO: Jeremy Bender
Employees: 174
Website: https://dayonebio.com/
BRISBANE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company...
Despite fears of a recession roiling the markets, analysts say these are the best stocks to buy with an average upside potential of 72%.
Here you can normally see the latest stock twits on DAWN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: